• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019

Download this press release (381 KB).

ROSEVILLE, MN – June 26, 2019 — Rebiotix, Inc., a Ferring Pharmaceuticals company, announced today that two members of their senior leadership team, Dr. Ken Blount, Chief Scientific Officer and Dr. Edward Burd, Head of Regulatory Affairs, will engage in key panel discussions at the 2019 Microbiome Movement – Drug Development Summit. The fourth annual summit will take place on June 26-28 in Boston, MA.

An established figure in the microbiome field, Dr. Blount will speak at the Microbiome Industry Leaders panel, where he will highlight the ongoing scientific and product-development challenges within the category, including highlights from Rebiotix’s clinical and microbiome research under the company’s innovative, investigational MRT™ drug platform.

In addition to the panel, Dr. Blount will deliver a presentation about Rebiotix’s pioneering MICROBIOME HEALTH INDEX™ (MHI™). The talk will focus on the company’s advances in developing the algorithm as a means to assess restoration of a patient’s microbiome communities after treatment with one of the company’s investigational MRT formulations. Currently, there are two formulations in clinical development – the lead candidate, RBX2660, is a liquid suspension in Phase 3; RBX7455, an investigational, first-of-its-kind lyophilized, non-frozen, room-temperature stable oral capsule formulation. Both formulations are currently focused on reducing recurrent Clostridioides difficile (C. diff) infection in adults.

“It is exciting to take part in an event that showcases innovations that harness the power of the microbiome. I am honored to participate in the Microbiome Industry Leaders panel to engage with other authorities in the field,” said Dr. Blount. “It’s events like these that enable us to come together, share ideas and shape the future prospect of microbiome-based therapies.”

Beyond scientific and clinical innovation in the category, the regulatory landscape for microbiota-based therapies continues to evolve. Initially outlined by the U.S. Food and Drug Administration (FDA) in 2013, additional standards specific to fecal microbiota transplantation (FMT) are anticipated in the near future and continue to be a focal point of discussion. To highlight the most recent developments and impact on the field, Dr. Burd will chair the Building Clear Regulatory Guidelines for Microbiome-based Therapeutics panel during the summit. The panel will address the growing complexities within microbiome product development, including donor testing, product characterization, and the dynamic international regulatory landscape for this emerging class of products.

“It is critical that the players in this space focus on developing safe products and procedures for the patients we serve,” said Dr. Burd. “With representatives from key microbiome companies and regulatory bodies offering commentary on this important topic, we can continue to emphasize the need for regulatory oversight and careful clinical investigation when it comes to patient-safety.”

Details for the panels and presentation are as follows:

Dr. Blount

  • Title: Microbiome Industry Leaders Panel Discussion
  • Date and Time: Thursday, June 27, 2019 8:30 AM
  • Title: A Prototype Biomarker for Microbiome Rehabilitation in Patients with Clostridium difficile Infections: Application to a Clinical Trial of a Lyophilized, Non-Frozen, Oral, Microbiota-Based Drug RBX7455
  • Date and Time: Friday, June 28, 2019 12:30PM; Track C

Dr. Burd

  • Title: Building Clear Regulatory Guidelines for Microbiome-based Therapeutics
  • Date and Time: Thursday, June 27, 2019 6:15 PM

For more information regarding the Microbiome Movement – Drug Development Summit 2019, please visit https://microbiome-summit.com.


About RBX2660 and RBX7455

RBX2660 is currently in Phase 3 clinical development for the reduction of recurrent Clostridioides difficile (C. diff) infection. RBX2660 has been granted Fast Track, Orphan and Breakthrough Status designations from the U.S. Food and Drug Administration (US FDA). Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, non-frozen, oral capsule part of a recently completed investigator-sponsored Phase 1 trial studied for the reduction of recurrent C. diff infection.

About Rebiotix Inc.

Rebiotix Inc., part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix has a diverse pipeline of investigational drug products built on its pioneering microbiota-based MRT™ drug platform. The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years. Today, over one third of the company’s research and development investment goes towards finding innovative and personalized healthcare solutions to help mothers and babies, from conception to birth. Founded in 1950, Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

For more information, please contact:

Courtney Jones
Marketing Manager
+1 (651) 705-8774
cjones@nullrebiotix.com

Press Releases Press Releases

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT